Pfizer and BioNTech to provide U.S. government with an additional 200 million doses of COVID-19 vaccine
|
28 July 2021 |
Pfizer and BioNTech announce collaboration with Biovac to manufacture and distribute COVID-19 vaccine doses within Africa
|
21 July 2021 |
Collaboration between AbbVie, Biogen and Pfizer creates world's largest browsable resource linking rare protein-coding genetic variants to human health and disease
|
15 July 2021 |
Pfizer and BioNTech to supply the European Union with up to 1.8 billion additional doses of COMIRNATY®
|
26 May 2021 |
Pfizer and BioNTech to provide COVID-19 caccine doses for olympic athletes at the 2020 Tokyo Games
|
06 May 2021 |
Pfizer acquires Amplyx Pharmaceuticals
|
28 April 2021 |
Pfizer-BioNTech announce positive topline results of pivotal COVID-19 vaccine study in adolescents
|
31 March 2021 |
Pfizer initiates Phase 1 study of novel oral antiviral therapeutic agent against SARS-CoV-2
|
24 March 2021 |
Real-world evidence confirms high effectiveness of Pfizer-BioNTech COVID-19 vaccine and profound public health impact of vaccination one year after pandemic declared
|
11 March 2021 |
Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants
|
25 February 2021 |
Pfizer and BioNTech commence global clinical trial to evaluate COVID-19 vaccine in pregnant women
|
18 February 2021 |
Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY®
|
04 January 2021 |
Pfizer and BioNTech to supply the U.S. with 100 million additional doses of COVID-19 vaccine
|
23 December 2020 |
Pfizer and BioNTech receive authorization in the European Union for COVID-19 vaccine
|
21 December 2020 |
Pfizer and BioNTech receive CHMP positive opinion for their COVID-19 vaccine
|
21 December 2020 |
Pfizer and BioNTech celebrate historic first authorization in the U.S. of vaccine to prevent COVID-19
|
14 December 2020 |
Pfizer and BioNTech receive FDA Advisory Committee vote supporting potential first Emergency Use Authorization for vaccine to combat COVID-19 in the U.S.
|
11 December 2020 |
Pfizer and BioNTech announce publication of results from landmark Phase 3 trial of BNT162b2 COVID-19 vaccine candidate in The New England Journal of Medicine
|
10 December 2020 |
Pfizer and BioNTech achieve Health Canada authorization for their vaccine to combat COVID-19
|
09 December 2020 |
Pfizer and BioNTech achieve first authorization in the world for a vaccine to combat COVID-19
|
02 December 2020 |